News

NeurogesX has reported the preliminary results of a short-term clinical study (Study C123) of Qutenza in patients with postherpetic neuralgia (PHN), following pretreatment with an FDA-approved topical anesthetic.

Merck & Co. has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), recommending expanded marketing authorisation for ISENTRESS (raltegravir) in combination with

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA), has issued a positive opinion for the marketing authorization of Regeneron’s rilonacept in

Teva has entered into an agreement with Ortho-McNeil-Janssen to settle the patent infringement lawsuit in the US District Court for the District of New Jersey. It is related

Merck & Co. has proposed a settlement, subject to Court approval, to resolve litigation challenging the planned merger between Merck and Schering-Plough and seeking other forms of relief.

Germany- based Merck has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMEA) for Cladribine Tablets, an investigational oral formulation of cladribine, for patients with

Roche posts sales figure of CHF24,006m for the six month ended period, 2009. Net income for the company was CHF4,051m, a decrease of 29% compared to the previous

Thermo Fisher Scientific has reported that revenues decreased 8% to $2.48 billion in the second quarter of 2009, compared with $2.71 billion in the 2008 quarter. GAAP diluted

FDA has approved a new use for Eli Lilly’s osteoporosis drug – Forteo [teriparatide (rDNA origin) injection]. The drug is to treat osteoporosis associated with sustained, systemic glucocorticoid